Chronic obstructive pulmonary disease (COPD) exacerbation and allergic bronchopulmonary aspergillosis (ABPA), in spite of sharing common features such as airway inflammation, airflow obstruction, and mucus hypersecretion, differ significantly from each other. We report a case of ABPA that was unsuccessfully treated as a COPD exacerbation. The history of non-exertional progressive dyspnea, absence of a symptom-free interval, and hemoptysis combined with a minimal, distant smoking history and prior employment at a fertilizer plant favor a diagnosis other than COPD exacerbation. The patient's disease progression and delay in diagnosis testify to the sway of cognitive biases. This case serves as a reminder that generating a thorough differential diagnosis early in a patient's care prevents misdiagnoses and hastens the initiation of definitive therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243184 | PMC |
http://dx.doi.org/10.1016/j.rmcr.2020.101089 | DOI Listing |
Afr J Prim Health Care Fam Med
December 2024
Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.
This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms.
View Article and Find Full Text PDFObjective: The purpose of the study was to examine the association between short-acting beta agonist (SABA), antibiotic and oral corticosteroid (OCS) use and mortality and cardiopulmonary outcomes in chronic obstructive pulmonary disease (COPD).
Design: Retrospective cohort study using administrative health data from 1 April 2011 to 31 March 2020.
Setting: Alberta, Canada.
Eur Respir Rev
January 2025
Population Health Sciences, King's College London, London, UK.
Introduction: Acute exacerbations of COPD (AECOPD) often involve mucus hypersecretion. Thus, management of sputum retention is critical. However, the use of airway clearance techniques (ACTs) in people with AECOPD across different healthcare settings and factors influencing their selection remain unclear.
View Article and Find Full Text PDFEur Respir Rev
January 2025
Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium
Introduction: Pulmonary rehabilitation is underutilised in patients after an acute exacerbation of COPD (AECOPD). Retrieving information regarding the setting, training modalities and the uptake and adherence to exercise interventions for these individuals in a vulnerable state could potentially guide future research.
Aim: To provide a comprehensive review of the existing literature on the content, uptake and adherence of different exercise interventions for patients after an AECOPD.
Lung
January 2025
Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Background: Guidelines specify steroids as therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the duration of survival benefit associated with steroids and the optimal dosage of nebulized budesonide (NB) during hospitalization remain unclear.
Methods: We conducted a retrospective study of hospitalized AECOPD patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!